Multidrug therapeutic challenges in leprosy

International Journal of Dermatology

Volumn 36, Issue 7, 1997, Pages 493-496

  Jain, Sanjiv ^a,b   Sehgal, Virendra N ^b   Sehgal, Wendra N ^a  

^a Skin Care Centre   (India)

^b Sehgal Nursing Home   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

DRUG EFFICACY; DRUG USE; HUMAN; LEPROSY; MYCOBACTERIUM LEPRAE; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 0030738197     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1997.00234.x     Document Type: Review

References (48)

1. Jopling WH, McDougall AC. Handbook of Leprosy, 4th edn. London: Heinemann Professional Publishing, 1988: i.
2. Sheperd CC, Levy L, Fasal P. Further experience with the rapid bactericidal effect of rifampicin on Mycobacterium leprae in man. Am J Trop MedHyg 1976523:1120-1114.
3. Levy L, Sheperd CC, Fasal P. The bactericidal effect of rifampicin on M. leprae in man: (a) single doses of 600, 900 and 12.00 mg, and (b) daily doses of 300 mg. lut JLepr 1976; 44:183-187.
4. Anonymous. Chemotherapy of Leprosy for Control Programmes. Report of a WHO Study Group. Geneva, World Health Organization, 1981. (WHO Technical Report Series, No. 675.)
5. Anonymous. WHO Expert Committee on Leprosy. Fifth Report. Geneva, World Health Organization, 1977. (WHO Technical Report Series, No. 607.)
6. Jacobson RR, Hastings RC. Rifampicin-resistant leprosy. Lancet 1976; II: 1304-1305.
7. Warndorff-van Diepen T. Clofazimine-resistant leprosy, a case report. Int J Lepr 1982; 50:139-142..
8. Walcott RR, Ross H. Exacerbation of leprosy during present day treatment. Int J Lepr 1953; 21:437-440.
9. Pettit JHS, Rees RJW. Sulphone resistance in leprosy: an experimental and clinical study. Lancet 1964; II: 673-674.
10. London F. Primary sulphone resistance. Lepr Rev 1977; 48:51.
11. Jacobson RR, Hastings RH. Primary sulphone resistant leprosy. IntJ Lepr 1978; 46:116.
12. Waters MFR, Laing ABG, Rees RJW. Proven primary dapsone resistance in leprosy -a case report. Lep Rev 1978; 49:12.7-130.
13. Girdhar BK, Sreevatsa, Desikan KV. Primary sulphone resistance. Lep Ind 1978; 50: 352-355.
14. Pearson JMH. The problem of dapsone resistant leprosy. IntJ Lepr 1981; 49:417-42.0.
15. Waters MFR, Rees RJW, McDougall AC, Neddell AGM. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological, and histopathological assessment and findings of viable leprosy bacilli. Lep Rev 1974; 45: 288-298.
16. Rees RJW, Waters MFR, Pearson JMH, et al. Long term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. IntJ Lepr 1976; 44: 159-169.
17. Sehgal VN, Bhattacharya SN, Jain S. Relapse or late reversal reaction? IntJ Lepr 1990; 58:118-120.
18. Sehgal VN. Clinical Leprosy, 3 rd edn. New Delhi: Jaypee Bros, 1993:182-189.
19. Sehgal VN, Jain S. Persisters, relapse (reactivation), drug resistance and multidrug therapy (MDT). J Dermatol (Tokyo) 1996; oo: oo-oo.
20. Waters MF. Chemotherapy of leprosy -current status and future prospects. Trans R Soc Trop Med Hyg 1993; 87: 500-503.
21. Sehgal VN, Joginder. Slit-skin smear in leprosy. Int J Dermatol 1990; 29:9-16.
22. Prabhakaran K, Harris EB, Randhawa B, et al. Use of keta-lactam/beta lactamase inhibitor combinations as antimycobacterial agents. Microbiol 1993; 76: 251-261.
23. Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental M. leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 571-581.
24. Gelber RH. Minocycline studies in mice: a promising agent for the treatment of leprosy. IntJ Lepr 1986: 54: 722-723.
25. Gelber KH. Activity of minocycline in Mycobacteriiim infected mice. J Infect Dis 1987; 156: 236-239.
26. Gelber RH, Fukuda K, Byrd S, et al. A clinical trial of minocycline in lepromatous leprosy. Br Med J 1992; 304:91-92.
27. Gelber RH, Sin P, Tsang M, et al.- Effect of low level and intermittent minocycline therapy on growth of M. leprae in mice. Antimicrob Agents Chemother 1991; 35: 992-994.
28. Ji B, Jamet P, Perani EG, et al. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in the treatment of lepromatous leprosy. J Infect Dis 1993; 168:188-190.
29. Gelber RH, Murray LP, Siu P, et al. Efficacy of minocycline in single dose and 100 mg twice daily for lepromatous leprosy. IntJ Lepi 1994; 62: 568-573.
30. Fajardo TT, Jr, Villahermosa LG, de la Cruz EC, et al. Minocycline in lepromatous leprosy. Int J Lepr 1995; 63: 8-17.
31. Pavitheran K. Relapse of paucibacillary leprosy after short course multidrug therapy. lud J Lepr 1988; 60: 22.5-119.
32. Reddy PK, Mohinuddin SK. Pattern of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). IndJ Lepr 1988; 60: 581-588.
33. Revankar CR, Karjivkar VG, Gurav VJ, Gahpat R. Clinical assessment of paucibacillary leprosy under multidrug therapy -three year follow up study. Ind JLepr 1989; 61:355-359-
34. van Borkel W, Kist P, Noble S, O'Toole L. Relapses after multidrug therapy for leprosy: a preliminary report of-22 cases in West Nepal. Lepr Rev 1989; 60:45-50.
35. Katoch K, Ramanathan U, Natarajan M, et al. Relapses in paucibacillary patients after treatment with three short term regimens containing rifampicin. Int J Lepr 1989; 57: 458-464.
36. Gnugni A, Nadkarni NJ, Kini MS, Mehta VR. Relapses in paucibacillary leprosy after MDT -a clinical study. Int J Lep 1990; 58:19-24.
37. Paltyn SR, Husser JA, Baquillon G, et al. Evaluation of five treatment regimens, using either caprona monotherapy or several doses of rifampicin in the treatment of paucibacillary leprosy. Lepr Rev 1990; 61: 151-156.
38. Boerrigter G, Ponnighaus JM, Fine PC-M, Wilson RJ. Four year follow up results of a WHO recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 1991; 59: 235-261.
39. Ekambarom V, Rao MK. Relapse rate in paucibacillary leprosy patients after multidrug therapy in North Arcot district. Ind J Lepr 1991; 63: 34-42.
40. Katoch K, Natrajan M, Yadav VS, Bhatia AS. Response of leprosy patients with single lesions to MDT. Acta Leprol I99559:I33-I37.
41. Anonymous. Risk of relapse in leprosy. The Leprosy Unit, World Health Organization. Ind J Lepr 1995; 67:13-26.
42. Faruque E, Hogue AK, Ahmed J, et al. Paucibacillary leprosy patients treated with multidrug therapy: four years experience (1988 to 1991) in Bangladesh. Nippon Rai Gakkai Zasshi 1994; 63:95-98.
43. WHO. Report of the Consultation on Technical and Operational Aspects of Leprosy, Male, Maldives. Geneva: World Health Organization, 1989. WHO/CDS/LEP/89.I.
44. Jamet PJB, Marchoux Chemotherapy Study Group. Relapse after long term follow up of multibacillary patients treated by WHO multidrug regimen. Int J Lepr 1995563:195-101.
45. Ponnighaus JM, Sterne JA. Epidemiological aspects of relapse in leprosy. Ind J Lepr 1995; 67: 35-44.
46. Ji B, Grosset JH. Ofloxacin for the treatment of leprosy. Acta Leprol 1991; 7: 321-326.
47. Franzblau SG, Parrilla ML, Clan GP. Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice. Int J Lepr 1993; 61: 66-69.
48. Gelber RH, Siu P, Tsang M, et al. Activity of combinations of dapsone, rifampicin, minocycline, clarithromycin, and sparfloxacin against M. leprae in infected mice. Int J Lepr !995J 63: 259-264.